Skip to main content

Table 1 Categorization of cytotoxic chemotherapies received during the study period

From: Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer

Category A

Category B

5-Fluorouracil

Capecitabine

Epirubicin

Docetaxel

Doxorubicin

Gemcitabine

Cyclophosphamide

Ixabepilone

Etoposide

Liposomal doxorubicin

Ifosfamide

Nab-paclitaxel

Methotrexate

Paclitaxel

Cisplatin

Vinorelbine

Carboplatin

 
  1. Novel agents were considered to be those approved since 1994 and are listed in Category B, while other available agents are included in Category A.